Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Matson Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while Matson Inc trades at $226.38 (market cap $6.81B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and Matson Inc pays a 0.67% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Matson Inc for 23 Days on average.
| HALO | MATX | |
|---|---|---|
Market Cap | $12.58B | $6.81B |
Volume | 2,179,278 | 255,080 |
Sector | Health | Industrials |
52-Week High | $115.22 | $238.60 |
52-Week Low | $61.63 | $88.05 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $14.49B | $7.41B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Matson (MATX) trades at $222.92, down 0.83% on the day, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $4.27 versus $3.79 expected, and maintains healthy profitability with a 13.41% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment toward the transportation services sector.
MATX presents a compelling investment case with solid earnings growth, attractive valuation metrics (P/E of 15.37), and strong analyst support (66.7% buy ratings). Key risks include freight market volatility and competitive pressures, but the company's raised full-year outlook and dividend payments provide stability. The stock offers potential upside with Wall Street analysts projecting 27.3% price target upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
